MAIA Biotechnology, Inc.
Company Snapshot: MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Nov 17 2023 MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
- Nov 17 2023 MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
- Nov 15 2023 MAIA Biotechnology Announces $4 Million Registered Direct Offering
- Nov 10 2023 FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma